Cardiac Biomarkers Market Will Grow At Highest Pace Owing To Increasing Prevalence Of Cardiac Diseases

Cardiac Biomarkers Market

The cardiac biomarkers market comprises products that help in the detection of cardiac dysfunction and injuries. Cardiac biomarkers include troponin, CK-MB, myoglobin, Ischemia Modified Albumin (IMA), and others that assist physicians in diagnosing conditions associated with heart attacks, cardiomyopathy, myocarditis, and other cardiovascular diseases. The cardiac biomarkers testing is non-invasive, easy to perform, and provides quick and reliable results. The rising burden of cardiovascular diseases due to unhealthy lifestyle choices such as smoking, alcohol consumption, lack of physical activity along with increasing geriatric population are major factors augmenting the demand for cardiac biomarkers.

The Global Cardiac Biomarkers Market is estimated to be valued at US$ 11331.71 Mn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Cardiac Biomarkers are Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Randox Laboratories Ltd., Siemens Healthineers, and BioMérieux SA.
The growing prevalence of cardiovascular diseases and rising geriatric population are major factors augmenting the demand for cardiac biomarkers globally. As per WHO estimates, cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year.
Technological advancements in Cardiac Biomarker Market Size testing with rapid diagnostic platforms, high sensitivity & specificity cardiac biomarker assays are expected to witness high growth over the forecast period. POC testing platforms are gaining popularity for cardiac biomarker testing for quick diagnosis in hospitals and diagnostic centers.

Market Trends
Increased adoption of immunoassay technology - Immunoassay technology has emerged as a promising technology for cardiac biomarker testing with benefits such as high sensitivity, accuracy, and faster results. Continuous innovation to develop new generation immunoassay platforms will drive the market growth.
Focus on preventive healthcare - Growing trend of preventive healthcare and screening for cardiovascular risk assessment is fueling the demand for cardiac biomarker testing. This helps in early diagnosis and disease management.

Market Opportunities
Development of novel cardiac biomarkers - Research focus on discovery of new generation, high sensitivity cardiac biomarkers for improved diagnosis will create new revenue pockets.
Increased healthcare spending in emerging economies - Emerging countries are witnessing increased healthcare expenditure focused on management of chronic diseases including CVDs. This presents significant opportunity for players in cardiac biomarkers market.

Impact of COVID-19 on Cardiac Biomarkers Market Growth
The COVID-19 pandemic significantly impacted the growth of the cardiac biomarkers market globally. During the initial lockdown phase, there was a decline in regular healthcare visits and diagnostic tests. This led to reduced demand for cardiac biomarkers testing. However, as COVID-19 infection is known to cause cardiac issues, the demand for cardiac biomarkers rose exponentially to evaluate and manage cardiac complications in COVID patients. Hospitals focused on testing COVID patients with pre-existing cardiovascular conditions using cardiac troponin and BNP assays. With rising hospitalizations and mortality due to cardiovascular implications of COVID, the utility of high sensitivity assays gained prominence for timely diagnosis and management. In the post-pandemic era, focus on cardiac health monitoring and preventing long term cardiac sequalae of COVID is expected to further augment the demand. Advanced high sensitivity assays with wider detection capabilities can help in cardiovascular risk stratification of recovered patients as well.

Cardiac Biomarkers Market in North America
North America dominates the global cardiac biomarkers market accounting for the largest share in terms of value. This is attributed to factors such as rising geriatric population susceptible to cardiac diseases, developed healthcare infrastructure and higher diagnostic testing rates. The United States represents the most lucrative cardiac biomarkers market in the region owing to presence of major players, favorable reimbursement policies, technological advancements and increasing adoption of cardiac POC testing. However, high medical costs remain a concern.

Fastest Growing Region for Cardiac Biomarkers Market
The Asia Pacific region is poised to be the fastest growing market for cardiac biomarkers globally during the forecast period. This is due to improving healthcare infrastructure, increasing medical tourism, rising awareness regarding cardiac diagnostics and expanding patient pool of cardiac disorders like hypertension, diabetes in developing countries. Additionally, growing geriatric population prone to cardiac ailments, favorable government initiatives and presence of emerging economies with huge patient pools offer significant growth opportunities. However, lack of proper regulatory guidelines and limited awareness continue to challenge the regional market to realize its full potential.

Get more insights on Cardiac Biomarkers Market